Search Results
Sep 09, 2026, 00:47 ET Global Times: Silk Road Maritime Forum kicks off in Xiamen with focus on shared growth, open cooperation
resilient future of prosperity and development," she noted.Permanent Secretary of Nigeria's Federal Ministry of Industry, Trade and Investment Chris Osa Isokpunwu stated that the forum's theme aligns closely with the current direction of Nigeria's economic development."For us, the Silk Road Maritime
More news about: Global Times
Sep 04, 2026, 13:42 ET Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
(Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).Modafinil Tablets (RLD Provigil®) had estimated annual sales of USD 70.7 million in the U.S. (IQVIA MAT Jul 2026).About
More news about: Lupin Pharmaceuticals
Sep 01, 2026, 08:31 ET JOMS Study: Jaw Pain Condition May Signal Higher Risk for Sleep Apnea, Research Finds
Sept. 1, 2026 /PRNewswire/ -- Patients diagnosed with a temporomandibular disorder (TMD) are at increased risk for obstructive sleep apnea (OSA) compared to people without the disorder, according to a study published in the Journal of Oral and Maxillofacial Surgery (JOMS), the peer-reviewed
More news about: American Association of Oral and Maxillofacial Surgeons
Aug 31, 2026, 07:00 ET New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist
More news about: Eli Lilly and Company
Aug 26, 2026, 06:45 ET Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
Aug 17, 2026, 16:55 ET ByteLens muuttaa operaattoridatan jatkuvasti karttuvaksi tiedoksi
operatiivisen älykkyyden tuotteensa. Se varoittaa vioista ennen kuin ne vaikuttavat asiakkaisiin, paikantaa niiden syyn sekunneissa eri toimittajien ja verkon osa-alueiden välillä ja korjaa operaattorin hyväksymät vikatyypit. Ihmisen harkintaa käytetään siellä, missä sitä tarvitaan. Hajanainen data ilman
More news about: Bytelens
Aug 17, 2026, 09:00 ET ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health
Americans are believed to be suffering from OSA, yet an estimated 80% of such adults remain undiagnosed and untreated. The diagnosed sleep apnea market alone is estimated at $8 billion, which reflects only a fraction of the category's full opportunity, given how many OSA sufferers have yet to be identified and
More news about: Cathay Capital
Aug 12, 2026, 10:00 ET Following a Season of Consistent Progress, Íñigo López de la Osa Franco is Ready for the FEI World Championship
concentrated, performing at our best and making the most of an experience of this magnitude." – Íñigo López de la Osa Franco The 2026 season marks López de la Osa Franco's second campaign on the Longines Global Champions Tour, where he has been competing in the world's most prestigious
More news about: Savoir Sport
Aug 12, 2026, 05:00 ET SISQUAL® WFM toimittaa Norjan poliisille työvoiman hallintaratkaisun (WFM)SISQUAL® WFM on voittanut yhdessä paikallisen kumppaninsa Devoteamin kanssa merkittävän julkisen tarjouskilpailun työvoiman hallintaratkaisun (WFM) toimittamisesta Norjan poliisille
toteuttamiseen asti. Teemme yhteistyötä viiden johtavan pilviteknologiatoimittajan kanssa: Microsoft, Google, AWS, Salesforce ja ServiceNow. Olemme osa Pariisissa päämajaansa pitävää Devoteam Groupia ja toimimme yli 20 maassa yli 11 000 konsultin voimin eri puolilla EMEA-aluetta.Lue lisää osoitteessa:
More news about: SISQUAL® WFM
Aug 11, 2026, 06:30 ET DarioHealth Reports Second Quarter 2026 Financial Results
with weight changes, sleep disruption, metabolic changes and increased cardiometabolic riskDario Sleep addresses obstructive sleep apnea ("OSA"), a significant contributor to cardiometabolic disease and rising healthcare costsExtended Into Provider-Backed CareExpanded
More news about: DarioHealth Corp.
Aug 05, 2026, 10:00 ET Cisionin raportti varoittaa, että brändit ovat ajautumassa kalliiksi käyvään "datan pirstoutumisen ansaan"
laajempaa uskottavuutta ja näkyvyyttä.Brändit, jotka luottavat pelkästään mediaseurantaan, olisivat huomanneet trendin paljon myöhemmin, kun suuri osa edelläkävijän eduista oli jo hyödynnetty."Brändit, jotka yhdistävät signaalinsa, näkevät tulevan kehityksen ja toimivat sen mukaisesti. Ne, jotka
More news about: Cision Ltd.
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
mildly reduced ejection fraction and obesity.MARITIME-OSA-1, a Phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea on positive airway pressure therapy and living with obesity or overweight.MARITIME-OSA-2, a Phase 3 study of MariTide, is enrolling adults living
More news about: Amgen
Aug 04, 2026, 07:30 ET Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
sleep apnea (OSA), a significant contributor to cardiometabolic disease and rising healthcare costs.Published research has shown that untreated OSA patients incur approximately 2.5× higher annual healthcare costs than individuals without OSA.2 Cardiometabolic patients with OSA also generate
More news about: DarioHealth Corp.
Jul 30, 2026, 22:10 ET Apnimed Announces Pricing of Upsized Initial Public Offering
living with OSA. If approved, we believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed's
More news about: Apnimed, Inc.
Jul 23, 2026, 06:45 ET Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
Jul 16, 2026, 07:19 ET The Silent Sleep Crisis: Apollo Experts Warn That 80-90% of Sleep Apnoea Cases Go Undiagnosed
increased the risk of sleep disorders. Nearly one in five middle-aged working men and women are estimated to be at high risk of Obstructive Sleep Apnoea (OSA)."Snoring should never be dismissed as a harmless habit," said Dr. Jayalakshmi T. K., Senior Consultant - Pulmonology, Apollo Hospitals
More news about: Apollo Hospitals
Jul 16, 2026, 06:00 ET HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep-Disordered Breathing Analysis
- FDA 510(k) Clearance (K253390) Validates AI-Based Classification of OSA, CSA, and MSA- Subtype-Specific Respiratory Event Analysis Improves Diagnostic Precision and Supports Next-Generation Digital Biomarker Development- Advanced AI Analysis Using Multi-Channel
More news about: HoneyNaps
Jul 14, 2026, 10:36 ET Cision lisää CisionOneen tekoälyhakunäkyvyyden seurannan ja auttaa PR-tiimejä seuraamaan, miten brändit näkyvät tekoälyn vastauksissa
enemmän tiedonhakuun, tuotesuositusten etsimiseen ja päivittäisen tiedon hankkimiseen. Siksi tekoälyn tuottamista vastauksista on tulossa yhä tärkeämpi osa sitä, miten brändit löydetään ja millainen käsitys niistä muodostuu. Tämä asettaa nykyajan viestintätiimeille uuden näkyvyyshaasteen: Enää ei riitä,
More news about: Cision Ltd.
Jul 14, 2026, 08:00 ET Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed's NDA
More news about: Apnimed, Inc.
Jul 01, 2026, 08:00 ET Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA, including the SynAIRgy study,
More news about: Apnimed, Inc.
Jun 29, 2026, 09:56 ET Smartee präsentiert auf der EOS 2026 Technologien zur Unterkiefer-Repositionierung und Lösungen für Schlaf-Aligner
und – sofern dies nach den geltenden lokalen Vorschriften zulässig ist – bei leichtem bis mittelschwerem obstruktivem Schlafapnoe-Hypopnoe-Syndrom (OSA) konzipiert ist.Das Portfolio umfasst Smartee SA, eine Unterkiefer-Protrusionsschiene, die durch gezielte Technologie die Atemwege erweitert und
More news about: Smartee Denti-Technology
Jun 29, 2026, 08:34 ET Smartee destaca su tecnología y soluciones en EOS 2026
pacientes con ronquidos primarios y, donde lo permitan las normativas locales aplicables, para el síndrome de apnea-hipopnea obstructiva del sueño (OSA) leve a moderado.La gama incluye Smartee SA, un dispositivo de avance mandibular diseñado para dilatar las vías respiratorias y,
More news about: Smartee Denti-Technology
Jun 29, 2026, 06:34 ET Smartee Highlights Mandibular Repositioning Technology and Sleep Aligner Solutions at EOS 2026
patients with primary snoring and, where permitted under applicable local regulations, mild to moderate obstructive sleep apnoea hypopnoea syndrome (OSA).The portfolio includes Smartee SA, a mandibular advancement device designed to dilate airways and thereby enhance unobstructed oxygen delivery
More news about: Smartee Denti-Technology
Jun 25, 2026, 06:45 ET What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
Jun 18, 2026, 10:00 ET Cision lanseeraa CisionOne-alustalle tekoälypohjaisen medianäkyvyysanalyysin, joka auttaa PR-tiimejä siirtymään uutisoinnista käytännön toimiin
toimenpiteiden suositteluunVirstanpylväs Cisionin tekoälyn kehityksessä Tekoälypohjainen medianäkyvyysanalyysin lanseeraus on osa Cisionin jatkuvaa panostusta tekoälypohjaisiin viestinnän työnkulkuihin. Yhdistämällä seurannan, analysoinnin, raportoinnin ja toimet yhdelle alustalle,
More news about: Cision Ltd.